ZNF709 belongs to the zinc finger protein family, which is characterized by its ability to bind DNA and influence transcriptional regulation. This family of proteins is crucial in a wide array of cellular processes, including growth, development, differentiation, and apoptosis. ZNF709, specifically, is thought to function as a transcriptional regulator, binding to DNA at specific gene sites to modulate the expression of genes involved in these fundamental biological processes. The exact targets and mechanisms of ZNF709 are not fully delineated but are believed to play a significant role in the regulation of genes that maintain cellular integrity and respond to environmental stimuli.
The inhibition of ZNF709 can occur through various molecular mechanisms, potentially impacting its role as a transcriptional regulator. One primary method of inhibiting ZNF709 involves interfering with its ability to bind to DNA. This could be achieved through the competitive binding of other molecules that mimic the DNA binding sites of ZNF709, thereby blocking its regulatory effects on gene expression. Another mechanism of inhibition could be the alteration of the expression levels of ZNF709 itself. Downregulation of ZNF709 at the transcriptional level, whether through the action of repressive transcription factors or through epigenetic modifications such as DNA methylation or histone modification, could reduce the overall levels of the protein, thus diminishing its impact on transcriptional regulation. Additionally, post-translational modifications such as phosphorylation, ubiquitination, or sumoylation could alter the stability, localization, or DNA-binding ability of ZNF709, further modulating its activity. These mechanisms ensure that the activity of ZNF709 is tightly controlled within the cell, allowing precise regulation of gene expression that is responsive to the cellular environment and the needs of the organism. Such regulatory complexity highlights the significance of ZNF709 in maintaining cellular functions and the potential consequences of its dysregulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
Affects the bromodomain-containing proteins and can indirectly affect ZNF709's ability to bind to specific regions of DNA, thereby modulating its transcriptional activity. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
This compound is an inhibitor of the histone methyltransferase EZH2, which can affect the chromatin state and thus the transcriptional activity of ZNF709. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
As an MDM2-p53 interaction inhibitor, it can affect the p53 pathway, which may interact with ZNF709 in certain contexts. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor that can affect cell cycle progression, a cellular process that ZNF709 may be involved in, thus indirectly inhibiting the protein. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR inhibitor that disrupts the MAPK and PI3K pathways. These pathways may have crosstalk with ZNF709-related pathways. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $92.00 $243.00 $306.00 | ||
As another EZH2 inhibitor, GSK126 can modify the chromatin landscape, which can indirectly influence the transcriptional activity of ZNF709. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
As a PARP inhibitor, it can affect DNA repair mechanisms, thereby indirectly affecting pathways that may involve ZNF709. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Rho-associated protein kinase (ROCK) inhibitor that can affect cellular processes like apoptosis, which ZNF709 may modulate. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor affecting protein degradation, altering the turnover of ZNF709 or its interacting proteins. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
An inhibitor of the TGF-beta signaling pathway, which could affect cellular processes and pathways where ZNF709 is involved. | ||||||